Recursion Pharmaceuticals, Inc. (RXRX) Ownership
RXRX ownership summary
as of October 18, 2026- Institutions
- 64.4% of shares outstanding
- Insiders
- 1.83% of shares outstanding
- Shares outstanding
- 535.3M
- Float
- 518.5M shares available to trade
- Short interest
- 30.89% 157.9M shares short
- Days to cover
- 7.82 short interest down 11.6% vs prior month
- Institutions 64.44%
- Insiders 1.83%
- Other investors 33.73%
RXRX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 9.38% | 50.3M | $174.3M | +7.1M (+16.5%) | June 30, 2026 |
| 2 | ARK Investment Management LLC | 7.71% | 41.3M | $143.2M | +1.1M (+2.8%) | June 30, 2026 |
| 3 | State Street Corp | 6.47% | 34.7M | $120.3M | +6.2M (+21.8%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 5.81% | 31.1M | $107.9M | +8.4M (+36.8%) | June 30, 2026 |
| 5 | Baillie Gifford & Co Limited. | 4.38% | 23.5M | $81.4M | −187,500 (−0.8%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 4.25% | 22.8M | $78.9M | +521,553 (+2.3%) | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 2.58% | 13.8M | $47.9M | +1.5M (+12.6%) | June 30, 2026 |
| 8 | SoftBank Group Corp | 2.54% | 13.6M | $47.3M | — | June 30, 2026 |
| 9 | MIC Capital Management UK LLP | 1.80% | 9.6M | $33.4M | +1 (0.0%) | June 30, 2026 |
| 10 | UBS Group AG | 1.67% | 8.9M | $31.0M | +3.8M (+75.4%) | June 30, 2026 |
| 11 | NORGES BANK | 1.27% | 6.8M | $23.7M | +1.1M (+19.1%) | June 30, 2026 |
| 12 | Data Collective IV GP, LLC | 1.11% | 5.9M | $20.6M | — | June 30, 2026 |
| 13 | Amova Asset Management Americas, Inc | 1.03% | 5.5M | $19.1M | +92,466 (+1.7%) | June 30, 2026 |
| 14 | Sumitomo Mitsui Trust Group Inc | 1.03% | 5.5M | $19.1M | +92,466 (+1.7%) | June 30, 2026 |
| 15 | Northern Trust Corp | 0.89% | 4.8M | $16.5M | +789,825 (+19.9%) | June 30, 2026 |
| 16 | Marshall Wace Asset Management Ltd | 0.88% | 4.7M | $16.3M | +1.8M (+63.9%) | June 30, 2026 |
| 17 | Charles Schwab Investment Management Inc | 0.77% | 4.1M | $14.3M | +329,488 (+8.7%) | June 30, 2026 |
| 18 | DCVC Opportunity Fund II GP, LLC | 0.74% | 4.0M | $13.7M | — | June 30, 2026 |
| 19 | The Goldman Sachs Group Inc | 0.73% | 3.9M | $13.6M | −2.1M (−35.4%) | June 30, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 0.65% | 3.5M | $12.0M | −44,425 (−1.3%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 33.0M shares and 3 cut 2.4M.
RXRX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Innovation ETF | 4.29% | 23.0M | $79.8M | −1.8M (−7.3%) | September 30, 2026 |
| 2 | Scottish Mortgage Ord | 3.39% | 18.2M | $63.0M | — | July 31, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 3.12% | 16.7M | $57.9M | −319,550 (−1.9%) | September 30, 2026 |
| 4 | Vanguard MStar Total Stk Mkt Idx Invest | 2.96% | 15.9M | $55.1M | −43,212 (−0.3%) | August 31, 2026 |
| 5 | ARK Genomic Revolution ETF | 2.58% | 13.8M | $47.9M | +33,800 (+0.2%) | September 30, 2026 |
| 6 | iShares Russell 2000 ETF | 2.48% | 13.3M | $46.2M | −153,536 (−1.1%) | September 30, 2026 |
| 7 | Vanguard Small Cap Index | 2.14% | 11.5M | $39.7M | +38,262 (+0.3%) | August 31, 2026 |
| 8 | WisdomTree Art Intelligence ETF USD Acc | 1.53% | 8.2M | $28.5M | — | September 30, 2026 |
| 9 | Vanguard MStar Small Cap Growth Indx Inv | 1.22% | 6.6M | $22.8M | −59,067 (−0.9%) | August 31, 2026 |
| 10 | Fidelity Small Cap Index | 1.04% | 5.6M | $19.4M | +37,659 (+0.7%) | July 31, 2026 |
| 11 | iShares Russell 2000 Value ETF | 0.82% | 4.4M | $15.2M | +6,650 (+0.2%) | September 30, 2026 |
| 12 | Vanguard Strategic Equity Inv | 0.73% | 3.9M | $13.5M | +3.9M (0.0%) | June 30, 2026 |
| 13 | iShares Biotechnology ETF | 0.69% | 3.7M | $12.9M | −28,176 (−0.8%) | September 30, 2026 |
| 14 | FT Nasdaq Artfcl Intllgnc and Rbtc ETF | 0.66% | 3.5M | $12.3M | — | September 30, 2026 |
| 15 | Vanguard US Growth Investor | 0.61% | 3.3M | $11.3M | — | June 30, 2026 |
| 16 | Amova ARK Disruptive Innovation A USD | 0.58% | 3.1M | $10.8M | −96,713 (−3.0%) | August 31, 2026 |
| 17 | Vanguard Russell 2000 ETF | 0.55% | 2.9M | $10.2M | +70,852 (+2.5%) | August 31, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.53% | 2.8M | $9.8M | +1,899 (+0.1%) | September 30, 2026 |
| 19 | Fidelity Extended Market Index | 0.49% | 2.6M | $9.1M | −36,132 (−1.4%) | August 31, 2026 |
| 20 | Vanguard Explorer Inv | 0.44% | 2.3M | $8.1M | +1.6M (+212.2%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RXRX insider transactions
latest 10| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | Blake Borgeson | Sell | $3.10 | 30,000 | $93,000 |
| 2026-03-17 | Ben R Taylor | Sell | $3.39 | 7,956 | $26,971 |
| 2026-03-09 | Najat Khan | Sell | $3.35 | 28,298 | $94,798 |
| 2026-02-18 | Ben R Taylor | Sell | $3.08 | 13,426 | $41,352 |
| 2026-02-03 | Blake Borgeson | Sell | $4.20 | 220,000 | $924,000 |
| 2026-01-06 | Blake Borgeson | Sell | $4.36 | 220,000 | $959,200 |
| 2025-12-29 | Ben R Taylor | Sell | $4.18 | 21,383 | $89,381 |
| 2025-12-22 | Najat Khan | Sell | $4.41 | 124,403 | $548,617 |
| 2025-12-02 | Blake Borgeson | Sell | $4.37 | 220,000 | $961,400 |
| 2025-08-18 | Najat Khan | Sell | $5.52 | 36,599 | $202,026 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RXRX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RXRX
Institutional investors own 64.4% of Recursion Pharmaceuticals's shares and insiders 1.83%. The largest holder is BlackRock Inc with 9.38% of the shares (50.3M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 3 reduced their stake in the latest filings. Short interest is 30.89% of the float, or 7.82 days of average trading volume. The share count rose 2,294.2% since 2019.
Related: RXRX analyst forecast, RXRX key metrics. See the RXRX stock overview for the latest quote and news.
RXRX ownership FAQ
Who owns the most Recursion Pharmaceuticals stock?
The largest shareholders of Recursion Pharmaceuticals are BlackRock Inc (9.38%), ARK Investment Management LLC (7.71%), State Street Corp (6.47%), Vanguard Portfolio Management, LLC (5.81%), Baillie Gifford & Co Limited. (4.38%).
What percentage of Recursion Pharmaceuticals is owned by institutions?
Institutions hold 64.4% of Recursion Pharmaceuticals's shares outstanding; insiders hold 1.83%.
Which funds own Recursion Pharmaceuticals?
The largest fund holders of Recursion Pharmaceuticals are ARK Innovation ETF (4.29%), Scottish Mortgage Ord (3.39%), State Street® SPDR® S&P® Biotech ETF (3.12%), Vanguard MStar Total Stk Mkt Idx Invest (2.96%), ARK Genomic Revolution ETF (2.58%).
What is Recursion Pharmaceuticals's short interest?
157.9M shares of Recursion Pharmaceuticals were sold short, 30.89% of the float; at the average daily volume it would take 7.82 days to cover.
Are insiders buying or selling Recursion Pharmaceuticals?
Of the latest 10 reported insider transactions in Recursion Pharmaceuticals (since August 18, 2025), 0 were purchases and 10 were sales.
How many shares of Recursion Pharmaceuticals are outstanding?
Recursion Pharmaceuticals has 535.3M shares outstanding, of which 518.5M are in the public float.